BB
Bristi Basu
University of Cambridge
Research areas: Medicine · Oncology · Ovarian cancer diagnosis and treatment · PARP inhibition in cancer therapy · Hepatocellular Carcinoma Treatment and Prognosis
0000-0002-3562-2868
Employment
-
University of Cambridge Clinical Principal Research Associate2025 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (208)
- Multi-stromal organoid co-culture modelling reveals epithelial-fibroblast heterogeneity in pancreatic cancer and pancreatitis. Save
- Abstract LB469: Pharmacokinetics of the EP4 antagonist HTL0039732, a CRUK first-in-human phase I trial in patients with advanced solid tumours Save
- Abstract A045: The 5G (Next Generation AGile Genomically Guided Glioma) Platform Trial – A First-in-world Adaptive Clinical Trial for Precision Treatment of Brain Tumours Save
- Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology. Save
- Abstract B014: CRISTAL-APC - A multi-center, open label Phase I/ II study of VP-002, a C-C motif chemokine receptor 1 (CCR1) inhibitor, in combination with nab-paclitaxel and gemcitabine (nPG) in patients with pancreatic ductal adenocarcinoma (PDAC) Save
- 948P Cancer Research UK first-in-human (FIH) phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 (HTL) as monotherapy and in combination with immunotherapy in patients with advanced solid tumours Save
- 967P Phase I/II study of the next-generation Nectin-4-targeting antibody–drug conjugate CRB-701 (SYS6002) in patients with urothelial and non-urothelial solid tumours Save
- A phase Ib, open-label trial of MOv18 IgE in patients with advanced ovarian cancer. Save
- MANIFEST: Multiomic Platform for Cancer Immunotherapy. Save
- Corrigendum to ‘A Phase Ib, Open-Label Trial Of MOv18 IgE In Patients With Advanced Ovarian Cancer’ [International Journal of Gynecological Cancer Volume 35, Issue 2 Supplement 1 (2025) #809] Save
- TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors. Save
- Barriers to publishing early phase clinical trials: the oncologists' perspective. Save
- A Phase Ib, Open-Label Trial Of MOv18 IgE In Patients With Advanced Ovarian Cancer Save
- Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. Save
- 1O The somatic mutation landscape of the normal and malignant pancreas Save
- 679TiP Cancer Research UK phase I/IIa trial of the prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist HTL0039732 as monotherapy and in combination with immunotherapy in patients (pts) with advanced solid tumors Save
- Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study. Save
- 391P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer Save
- Abstract CT035: Proof-of-concept and preliminary efficacy of triple IAP blockade to maximize immunogenic cell death and induce efficient adaptive immune response: First report on the ASTEROID phase 1 trial Save
- Abstract LB_A17: Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors Save